Innealta Capital’s BioCryst Pharmaceuticals BCRX Stock Holding History

Innealta Capital’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-70	Closed	-$433	–	321
2024 Q2	$433	Buy	+70	New	+$386	﹤0.01%	1498

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

Innealta Capital's BCRX Position: Q3 2024 in Review

Innealta Capital sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2024, closing a stake of 70 shares — an estimated $433 sold.

Innealta Capital first reported a position in BCRX in Q2 2024 and held it in 1 quarter. The position peaked at $433 in Q2 2024. 257 funds tracked by Wall St. Rank hold BCRX as of Q3 2024.

Innealta Capital reported no remaining BioCryst Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Innealta Capital sold 70 BioCryst Pharmaceuticals shares in Q3 2024, an estimated $433.
Innealta Capital first reported a position in BioCryst Pharmaceuticals in Q2 2024 and held it in 1 quarter.
Innealta Capital's BioCryst Pharmaceuticals position peaked at $433 in Q2 2024.
257 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2024.

Based on Innealta Capital's 13F filing for Q3 2024, filed 29 Oct 2024.